Hypothesis

DHEA (and its sulfated form DHEAS) functions as a zone‑restricted paracrine factor that preserves zona reticularis microvascular integrity by neutralizing glucocorticoid‑induced reactive oxygen species; age‑related loss of DHEA/DHEAS triggers oxidative microvascular rarefaction, which blunts the cortisol awakening response and impairs HPA negative feedback.

Rationale

• Zona reticularis lies at the adrenal periphery and receives the lowest oxygen tension, making it vulnerable to oxidative stress.
• Glucocorticoids stimulate NADPH oxidase activity in adrenal endothelial cells, increasing ROS.
• DHEA can be metabolized to androstenediol, a potent antioxidant, and DHEAS serves as a circulating reservoir that is locally hydrolyzed by sulfatases.
• Prior work shows DHEA supplementation reverses bone loss in adrenal insufficiency [https://pmc.ncbi.nlm.nih.gov/articles/PMC2729149/], but its vascular actions in the adrenal have not been tested.
• Low circulating DHEAS is linked to sarcopenia, osteoporosis, dementia, sexual disorders, and cardiovascular disease [https://pubmed.ncbi.nlm.nih.gov/23647054/].
• Dysregulation of the cortisol awakening response associates with chronic stress, cardiovascular disease, and worse frontal cortex‑related cognitive performance in older adults [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0152071] and is independently related to slower walking speed and poorer executive function [https://pubmed.ncbi.nlm.nih.gov/22366337/].
• The HPA axis's negative feedback sensitivity to end hormones declines with age [https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00054/full], and chronic stress can accelerate aging because the ability to terminate stress response systems is impaired in the elderly [same link].

Testable Predictions

1. In adrenal slices from aged rodents, exogenous DHEAS will reduce nitrotyrosine staining and increase capillary density (CD31+) specifically in the zona reticularis.
2. Restoring DHEAS will rescue the ex vivo cortisol awakening response (measured as a rapid cortisol rise after an ACTH pulse) to levels seen in young adult slices.
3. Pharmacological inhibition of sulfatase (with stearylamine) will mimic the aged phenotype: increased vascular rarefaction, higher ROS, and diminished CAR despite normal ACTH input.
4. Adrenal‑specific overexpression of SULT2A1 (enhancing DHEAS synthesis) in middle‑aged mice will delay the decline in CAR magnitude and preserve executive function performance in behavioral assays.

Experimental Approach

• Use young (3 mo) and aged (18‑month) adrenal glands; prepare 200 µm slices and treat with vehicle, DHEAS (100 nM), or sulfatase inhibitor.
• Quantify ROS (DHE fluorescence), nitrotyrosine, and capillary density via confocal microscopy.
• Measure cortisol release in response to a 15‑min ACTH pulse (10 nM) and calculate CAR magnitude.
• In vivo, generate AAV8‑SULT2A1 vectors targeted to the adrenal cortex; administer to 12‑month mice; after 8 weeks assess plasma DHEAS, CAR (via serial tail‑bleed after light‑onset), and cognitive performance (Y‑maze).

Potential Confounds

• Systemic effects of DHEAS on pituitary ACTH secretion; to control, use adrenal‑denervated or perifusion systems that isolate adrenal output.
• Sex differences: repeat experiments in both males and females to verify consistency.

Significance

If validated, this hypothesis would redefine DHEA decline as an active driver of HPA axis dysregulation rather than a mere biomarker, opening therapeutic avenues that target adrenal microvascular health to ameliorate age‑related stress intolerance and cognitive decline.